Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Colorcon
Baxter
Dow
Moodys

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Patent: 8,821,865

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,821,865
Title:High concentration anti-TNF.alpha. antibody liquid formulations
Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
Inventor(s): Neu; Michael (Edingen-Neckarahuasen, DE), Tschoepe; Markus (Hessheim, DE), Weber; Carsten (Maxdorf, DE), Fraunhofer; Wolfgang (Gurnee, IL), Redden; Laura (Glenview, IL), Gastens; Martin (Wachenheim, DE), Feick; Alexander (Allschwil, CH)
Assignee: Abbvie Biotechnology Ltd. (Hamilton, BM)
Application Number:13/294,692
Patent Claims:see list of patent claims

Details for Patent 8,821,865

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Abbvie Biotechnology Ltd. (Hamilton, BM) 2030-11-11 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Abbvie Biotechnology Ltd. (Hamilton, BM) 2030-11-11 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,821,865

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Moodys
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.